SCIENCE
T-sphaera Drug Conjugate
Taking advantage of T-sphaera’s higher binding ability, superior efficacy and lower toxicity,
we are researching and developing our proprietary TSDC platform.
About TSDC
TSDC is a new modality platform under development with the aim of replacing ADC’s A (Antibody) with T-sphaera.
* ADC: Antibody Drug Conjugate.
About TSDC
TSDC is a new modality platform under development with the aim of replacing ADC’s A (Antibody) with T-sphaera.
* ADC: Antibody Drug Conjugate.
Mechanism of Action
1Binding to receptors overexpressed in cancer cells
2Internalized into cancer cells through receptor-mediated endocytosis
3Releasing payload while the linker is cleaved.
TSDC’s Strengths Over Antibodies/ADCs
TSDC’s strengths facilitate us to enrich a wide range of pipelines that can replace conventional antibody treatments
| Strengths | Benefits |
|---|---|
| Drug binding ratio↑ | Higher efficacy at lower doses with improved medication compliance and convenience |
| Structural stability↑ | TSDCs incorporated with insoluble high-efficacy payloads |
| Immune side effects↓ | Decreased immune side effects due to the nature of human-derived proteins |
| Multi-specific target application↑ | Broader expandability by applying novel multi targets |